NASDAQ: CODX
Co-Diagnostics, Inc.CIK 0001692415 · SIC 3841 · Surgical & Medical Instruments
Micro
Revenue $622K
Assets $17M
as of Sep 10, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
8-K
Filed Sep 4, 2026
· Period ending Sep 2, 2026
Summary not yet generated.
8-K
Filed Sep 4, 2026
· Period ending Sep 3, 2026
Summary not yet generated.
Partner
Trade CODX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
10-Q
Filed Aug 13, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
8-K
Filed Aug 13, 2026
· Period ending Aug 13, 2026
Summary not yet generated.
8-K
Filed Jul 31, 2026
· Period ending Jul 30, 2026
Summary not yet generated.
424B5
Filed Jul 27, 2026
Summary not yet generated.
10-Q
Filed May 14, 2026
· Period ending Mar 31, 2026
Summary not yet generated.
10-K
Filed Mar 31, 2026
· Period ending Dec 31, 2025
Summary not yet generated.
424B5
Filed Dec 19, 2025
Summary not yet generated.
424B5
Filed Oct 28, 2025
Summary not yet generated.
10-K
Filed Mar 27, 2025
· Period ending Dec 31, 2024
Summary not yet generated.
10-Q/A
Filed Nov 3, 2020
· Period ending Jun 30, 2020
Summary not yet generated.
424B4
Filed Jul 14, 2017
Summary not yet generated.
424B4
Filed Jul 13, 2017
Summary not yet generated.
S-1/A
Filed Jul 10, 2017
Summary not yet generated.
S-1/A
Filed Jun 23, 2017
Summary not yet generated.
S-1/A
Filed Jun 9, 2017
Summary not yet generated.
S-1
Filed Apr 28, 2017
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 13, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Product revenue | 166,131 | 162,910 | 312,084 | 213,187 |
| Total revenue | 166,131 | 162,910 | 312,084 | 213,187 |
| Cost of revenue | 45,303 | 32,106 | 239,071 | 53,696 |
| Gross profit | 120,828 | 130,804 | 73,013 | 159,491 |
| Operating expenses | ||||
| Sales and marketing | 466,681 | 609,713 | 934,637 | 1,266,743 |
| General and administrative | 1,500,803 | 2,599,982 | 4,003,929 | 5,373,131 |
| Research and development | 4,152,287 | 4,687,459 | 10,086,358 | 9,557,478 |
| Depreciation and amortization | 201,840 | 291,414 | 457,285 | 571,859 |
| Total operating expenses | 6,321,611 | 8,188,568 | 15,482,209 | 16,769,211 |
| Loss from operations | (6,200,783) | (8,057,764) | (15,409,196) | (16,609,720) |
| Other income (expense), net | ||||
| Interest income, net | 17,493 | 12,158 | 24,469 | 25,759 |
| Realized gain on investments | - | 340,358 | - | 641,823 |
| Loss on disposition of assets | - | (9,004) | - | (9,004) |
| Gain (loss) on remeasurement of acquisition contingencies | (29,171) | 10,222 | 46,109 | 727,289 |
| Loss on equity method investment in joint ventures | (52,157) | (13,760) | (65,518) | (15,204) |
| Total other income (expense), net | (63,835) | 339,974 | 5,060 | 1,370,663 |
| Loss before income taxes | (6,264,618) | (7,717,790) | (15,404,136) | (15,239,057) |
| Income tax provision | 19,168 | 12,327 | 19,688 | 24,331 |
| Net loss | (6,283,786) | (7,730,117) | (15,423,824) | (15,263,388) |
| Other comprehensive loss | ||||
| Change in net unrealized gains on marketable securities, net of tax | - | (196,585) | - | (284,375) |
| Total other comprehensive loss | - | (196,585) | - | (284,375) |
| Comprehensive loss | (6,283,786) | (7,926,702) | (15,423,824) | (15,547,763) |
| Loss per common share: | ||||
| Basic and Diluted | (1.46) | (7.00) | (4.69) | (14.05) |
| Weighted average shares outstanding: | ||||
| Basic and Diluted | 4,309,997 | 1,103,614 | 3,287,417 | 1,086,054 |
| Diluted | 4,309,997 | 1,103,614 | 3,287,417 | 1,086,054 |
Condensed Consolidated Balance Sheets (Unaudited)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | 3,649,632 | 11,884,607 |
| Accounts receivable, net | 52,059 | 190,375 |
| Inventory, net | 841,669 | 992,397 |
| Income taxes receivable | 425 | 44,559 |
| Prepaid expenses and other current assets | 648,673 | 581,527 |
| Total current assets | 5,192,458 | 13,693,465 |
| Property and equipment, net | 1,975,111 | 2,272,098 |
| Operating lease right-of-use asset | 1,769,011 | 1,207,453 |
| Intangible assets, net | 7,219,000 | 7,219,000 |
| Investment in joint ventures | 435,051 | 350,569 |
| Total assets | 16,590,631 | 24,742,585 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | 1,078,380 | 1,878,225 |
| Accrued expenses | 899,183 | 865,301 |
| Operating lease liability, current | 784,261 | 662,258 |
| Contingent consideration liabilities, current | 72,927 | 119,036 |
| Deferred revenue | 28,644 | 14,800 |
| Total current liabilities | 2,863,395 | 3,539,620 |
| Long-term liabilities | ||
| Operating lease liability | 1,014,887 | 574,301 |
| Total long-term liabilities | 1,014,887 | 574,301 |
| Total liabilities | 3,878,282 | 4,113,921 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity | ||
| Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | - | - |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 5,040,580 shares issued and 4,878,957 shares outstanding as of June 30, 2026 and 2,256,654 shares issued and 2,095,031 shares outstanding as of December 31, 2025 | 70,484 | 67,700 |
| Treasury stock, at cost; 161,623 shares held as of June 30, 2026 and December 31, 2025, respectively | (15,575,795) | (15,575,795) |
| Additional paid-in capital | 124,015,023 | 116,510,298 |
| Accumulated deficit | (95,797,363) | (80,373,539) |
| Total stockholders’ equity | 12,712,349 | 20,628,664 |
| Total liabilities and stockholders’ equity | 16,590,631 | 24,742,585 |
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | (15,423,824) | (15,263,388) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 457,285 | 571,859 |
| Stock-based compensation expense | 432,866 | 1,455,493 |
| Common stock issued for financial advisory services | - | 135,000 |
| Change in fair value of acquisition contingencies | (46,109) | (727,289) |
| Non-cash lease expense | 1,031 | (2,003) |
| Realized gain on investments | - | (641,823) |
| Loss from equity method investment | 65,518 | 15,204 |
| Loss on disposition of assets | - | 9,004 |
| Provision for credit losses | 557 | (13,248) |
| Inventory obsolescence recoveries | (59,215) | (95,302) |
| Changes in assets and liabilities: | ||
| Accounts receivable | 137,759 | (65,150) |
| Prepaid expenses and other assets | (23,012) | 690,010 |
| Inventory | 209,943 | 83,399 |
| Deferred revenue | 13,844 | 5,000 |
| Income taxes payable | - | 23,290 |
| Accounts payable, accrued expenses and other liabilities | (765,963) | (3,213,100) |
| Net cash used in operating activities | (14,999,320) | (17,033,044) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (160,298) | (492,973) |
| Proceeds from maturities of marketable investment securities | - | 31,509,485 |
| Purchases of marketable securities | - | (6,588,577) |
| Investment in joint ventures | (150,000) | - |
| Net cash (used in) provided by investing activities | (310,298) | 24,427,935 |
| Cash flows from financing activities | ||
| Issuance of common stock related to private placement transaction and warrant exercises, net of offering costs | 2,739,973 | - |
| Issuance of common stock related to at-the-market offering, net of offering costs | 4,334,670 | 783,746 |
| Net cash provided by financing activities | 7,074,643 | 783,746 |
| Net increase (decrease) in cash and cash equivalents | (8,234,975) | 8,178,637 |
| Cash and cash equivalents at beginning of period | 11,884,607 | 2,936,544 |
| Cash and cash equivalents at end of period | 3,649,632 | 11,115,181 |
| Supplemental disclosure of cash flow information | ||
| Cash received for income taxes | 26,592 | - |
| Supplemental disclosure of non-cash investing and financing transactions | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | 1,029,215 | - |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗